New
This year’s American Academy of Dermatology (AAD) Annual Meeting is already in full swing in Boston.
Nicolle Maquignon, VIPOC General secretary, reports from the GVF session: "Amit G Pandya, President, welcomed the participants. His speech was, as usual, very warming and showed how much he cares for the patients: find new resources, spread good information, give emotional as well as educational support to the individuals with vitiligo, educate the doctors, empower people to live well with vitiligo. <...> Doctors and scientists focused on the role of the patients and the groups support, in their studies, and are more and more aware about the burden, showing and talking about “humanity” in their relations with the patients."
All eyes will be on Incyte tomorrow as it reveals details on two Phase III trials studying its JAK1/JAK2 inhibitor ruxolitinib cream for vitiligo. To recap, the FDA extended its review of ruxolitinib in vitiligo for three months from 18 April to 18 July. Ruxolitinib is currently available for atopic dermatitis under the brand name Opzelura, and a potential expansion to vitiligo is key for Incyte's plans to diversify its revenue base. A similar delay happened when the company sought FDA approval for the cream in atopic dermatitis, but it eventually received FDA approval in the mild-to-moderate setting in patients 12 years old and over.
Photo (c) Nicolle Maquignon: Prof. John Harris, MD, Department of Dermatology at the University of Massachusetts Medical School presents “The vitiligo pathogenesis and updated emerging treatments”
FAQOther Questions
- Shall I take vitamin D for my vitiligo?
Vitamin D plays a central role in the prevention of different inflammatory and chronic diseases. Consuming 1,000–4,000 IU (25–100 mcg) of vitamin D3 daily should be ideal for mo...
- Is vitiligo contagious?
Vitiligo is not contagious. This means it cannot be spread from person to person through physical contact, sharing personal items, or any other means of transmission. Vitiligo ...
- Any link between vitiligo and military service?
While there isn't specific research directly linking military service to the onset of vitiligo, it's critical to comprehend that vitiligo is a multifaceted disorder influenced b...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.